Table 1 Cohort characteristics by the new 5 tier Grade Groups (at biopsy)
From: Oncological outcomes in an Australian cohort according to the new prostate cancer grading groupings
Grade Groups | ||||||
|---|---|---|---|---|---|---|
Characteristics (N = 4268) | I | II | III | IV | V | p-valuea |
Total - n (%) | 1782 (42) | 1154 (27) | 647 (15) | 399 (9) | 286 (7) | |
Clinical characteristics | ||||||
Mean age - years (SD) | 66 (9) | 67 (9) | 70 (10) | 72 (9) | 74 (10) | <0.001 |
Median PSA - ng/mL (IQR) | 7 (5–10) | 8 (6–12) | 10 (7–16) | 11 (7–20) | 17 (8–20) | <0.001 |
Public patient - no. (%) | 952 (53) | 594 (51) | 316 (49) | 223 (56) | 190 (66) | <0.001 |
Presented with symptoms - no. (%) | 395 (22) | 229 (20) | 112 (17) | 80 (20) | 87 (30) | <0.001 |
Primary Treatment - n (%) | ||||||
Radical Prostatectomyb | 719 (40) | 592 (51) | 260 (40) | 130 (33) | 39 (14) | <0.001 |
Radiotherapyb,c (with curative intent) | 488 (27) | 356 (31) | 243 (38) | 136 (34) | 111 (38) | <0.001 |
Observation (AS or WW) | 488 (27) | 109 (9) | 75 (12) | 48 (12) | 49 (17) | <0.001 |
ADT alone | 31 (2) | 54 (5) | 47 (7) | 62 (15) | 71 (25) | <0.001 |
Outcomes | ||||||
PCa deathsd – no. (%) | 40 (2) | 52 (5) | 42 (7) | 48 (12) | 77 (27) | <0.001 |
Other deathsd – no. (%) | 157 (9) | 115 (10) | 75 (12) | 61 (15) | 34 (12) | <0.001 |
Biochemical recurrenced – no. (%) | 104 (11) | 136 (17) | 124 (29) | 70 (30) | 44 (37) | <0.001 |
PCa survival (5 yrs) - % (95% CI) | 98 (97–99) | 96 (95–97) | 95 (93–96) | 84 (80–88) | 64 (59–69) | <0.001 |
BCR free survival (5 yrs)e - % (95% CI) | 91 (89–93) | 84 (81–86) | 73 (68–77) | 70 (63–76) | 67 (57–75) | <0.001 |